Cannabis Group Weekly Alert – September 2019 | Dentons – JD Supra

In this week’s edition:

Trump reiterates his administration’s plan to respect state laws on cannabis DEA makes announcements on cannabis research applications and hemp legality Illinois approves its first adult-use dispensaries Several agencies comment on hemp and CBD Chocolate appears to botch cannabis potency testing And more… Federal

President Trump expressed support for a states’ rights approach to cannabis policy.  “We’re going to see what’s going on.  It’s a very big subject and right now we are allowing states to make that decision,” the President said.  “A lot of states are making that decision, but we’re allowing states to make that decision.”  The comments are consistent with the federal approach of non-enforcement that began in the Obama administration.

The Drug Enforcement Administration (DEA) announced it will process 33 long-delayed applications to grow cannabis to be used in research.  However, before accepting any pending applications, the DEA intends to propose new regulations, and the agency said that it would not license any entities that are currently growing cannabis under state law.  Additionally, the notice affirmed that, thanks to the 2018 Farm Bill, one form of cannabis—hemp—no longer requires DEA registration to grow or manufacture.

The Food and Drug Administration (FDA) opened a new public comment period to solicit input on pending proposals to reschedule cannabis under international treaties.  The previous comment period had been shorter than usual to accommodate an expected UN vote, which was later delayed.  The reopening is consistent with FDA statements earlier that the ability to comment would reopen if such a delay occurred.  Parties now have until September 30, 2019, to submit a comment.

Surgeon General Jerome Adams issued an advisory about the harms of cannabis use, particularly by young people and pregnant and nursing women.  The warning’s publication, which was funded by a $100,000 donation from

Read More Here...

Leave a Comment

Please Rate This Content*

Your email address will not be published. Required fields are marked *

Scroll to Top